With VisiGen in Hand, Invitrogen Hopes To Bolster Its Own Third-Gen Platform

An Invitrogen official said the company’s $20 million buy of the budding developer of a real-time, single-molecule sequencing-by-synthesis technology “increases our confidence that we will be the leader in the new genomics era unfolding before us.”

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.